<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194477</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA04308901</org_study_id>
    <nct_id>NCT03194477</nct_id>
  </id_info>
  <brief_title>Providing Unique Support for Health (PUSH) Study</brief_title>
  <official_title>Identifying and Engaging Urban HIV Infected and Uninfected YBMSM in Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project Narrative This 5-city proposal seeks to address HIV disparities among young (ages&#xD;
      15-24) Black and/or Latinx men who have sex with men (YBLMSM) and transgender women (YBLTW)&#xD;
      in a multilevel intervention to identify, engage and retain, high-risk HIV-uninfected and&#xD;
      HIV-infected urban YBMSM/TW in the HIV prevention and treatment cascade. The mobile-enhanced&#xD;
      engagement intervention (MEI) is driven by the expressed and self-determined needs of each&#xD;
      HIV infected and uninfected participant and includes care navigation, engagement, treatment&#xD;
      and adherence. MEI also includes a supplemental Screening, Brief Intervention, and Referral&#xD;
      for Treatment (SBIRT), to support YBLMSM/TW who face barriers accessing substance use&#xD;
      treatment. By building upon existing case management services and flexibility to be adapted&#xD;
      across ages and maturity and for prevention services, this intervention has the ability to&#xD;
      transform networks, HIV and prevention care in YBLMSM/TW in cities with very high primary and&#xD;
      secondary HIV transmission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Summary The U.S. National HIV/AIDS Strategy 2020 calls for increasing access to care&#xD;
      and improving outcomes of people living with HIV and targeting biomedical prevention efforts&#xD;
      (including access to pre-exposure prophylaxis [PrEP]) where HIV is most heavily concentrated.&#xD;
      Baltimore, MD; Washington, DC; Philadelphia, PA (BWP); and Tampa and St. Petersburg, FL. are&#xD;
      disproportionately burdened by high rates of new cases of HIV infection, with&#xD;
      disproportionate rates in young Black and/or Latinx men who have sex with men (YBLMSM) and&#xD;
      transgender women (YBLTW) aged 15-24. High incidence underscores the need for increased&#xD;
      identification, linkage and initiation in HIV and preventive care for YBLMSM. Grants focused&#xD;
      on high rates directly address NIH research priorities to reduce health disparities in the&#xD;
      incidence of HIV, in antiretroviral therapy (ART) outcomes or in high HIV prevalent or&#xD;
      high-risk areas.&#xD;
&#xD;
      This innovative proposal seeks to test, treat and retain YBLMSM/TW living in BWP along the&#xD;
      prevention and treatment continuum using the following aims:&#xD;
&#xD;
      Aim 1. Identify and recruit young (ages 15-24) Black and/or Latinx men who have sex with men&#xD;
      (YBLMSM) in 3 urban cities who are (1) HIV-infected, not virally suppressed; and (2)&#xD;
      high-risk HIV-uninfected YBLMSM, including gender variant and questioning men, using&#xD;
      respondent driven sampling (RDS) with targeted seed identification. Assigned female sex at&#xD;
      birth participants may be eligible to screen and participate in this aim to assist in&#xD;
      recruiting YBLMSM/TW; Aim 2. Compare the efficacy of two study arms (mobile-enhanced&#xD;
      engagement intervention (MEI) vs. standard of care (SOC)) to achieve sustained retention&#xD;
      (measured by â‰¥ 4 follow up visits per 18-months) and engagement in HIV care (measured by&#xD;
      durable viral suppression (HIV VL &lt; 20 copies/ml) and substance treatment among 240&#xD;
      HIV-infected YBLMSM who are not virally suppressed and recruited from RDS; and Aim 3. Modify&#xD;
      and implement mobile-enhanced intervention for 225 high-risk HIV-uninfected YBLMSM, recruited&#xD;
      from RDS to promote linkage, retention and engagement of pre-exposure prophylaxis (PrEP) and&#xD;
      substance treatment uptake over 18-months, comparing younger (15-19) and older (20-24)&#xD;
      participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Mobile-enhanced engagement interventions (MEI) to support 1) HIV viral suppression among HIV-positive, not virally suppressed participants; 2) HIV-PrEP uptake among high-risk HIV-negative participants; and 3) engagement in substance abuse treatment for HIV-positive and HIV-negative participants.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Care providers and investigators will not know which patients are randomized to intervention or control.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Suppression</measure>
    <time_frame>18-months</time_frame>
    <description>Durable viral suppression (VL &lt; 20 copies/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PrEP Uptake</measure>
    <time_frame>18-months</time_frame>
    <description>Engagement in HIV pre-exposure prophylaxis (PrEP) services</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engagement in substance abuse treatment services</measure>
    <time_frame>6-months</time_frame>
    <description>Defined as at least two substance abuse treatment visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">465</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Mobile-enhanced Engagement Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - SOC Case Management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care (SOC) case management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mobile-enhanced Engagement Intervention</intervention_name>
    <description>Mobile phone based enhanced case management intervention for HIV positive &amp; HIV negative young Black men who have sex with men.</description>
    <arm_group_label>Mobile-enhanced Engagement Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Natal Male Inclusion Criteria:&#xD;
&#xD;
          -  Assigned male at birth&#xD;
&#xD;
          -  15-24 years old&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Black/African American&#xD;
&#xD;
          -  Hispanic/Latino ethnicity&#xD;
&#xD;
          -  HIV positive, viral load of 20 or greater&#xD;
&#xD;
          -  HIV negative, at high risk of HIV acquisition&#xD;
&#xD;
          -  Sex with another male within last 12-months&#xD;
&#xD;
          -  No plans to move outside of the research catchment area in next 18-months&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Not currently taking pre-exposure prophylaxis (PrEP)&#xD;
&#xD;
          -  Not currently enrolled or planning to enrolled in an HIV vaccine trial&#xD;
&#xD;
          -  Not currently enrolled or planning to enroll in an HIV adherence intervention&#xD;
&#xD;
        Natal Male Exclusion Criteria:&#xD;
&#xD;
          -  Birth-identified female&#xD;
&#xD;
          -  under age 15&#xD;
&#xD;
          -  Over age 24&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  No sex with another male in prior 12-months&#xD;
&#xD;
          -  Not Black/African American or Hispanic identified&#xD;
&#xD;
          -  HIV-positive, virally suppressed&#xD;
&#xD;
          -  HIV-negative, not at high risk of HIV acquisition&#xD;
&#xD;
          -  Unable or unwilling to provide consent for study participation&#xD;
&#xD;
          -  Unable or unwilling to return for study visits&#xD;
&#xD;
          -  Unwilling to provide an oral, blood or urine specimen for testing&#xD;
&#xD;
          -  Currently taking pre-exposure prophylaxis (PrEP)&#xD;
&#xD;
          -  Active or previous participation in an HIV vaccine trial&#xD;
&#xD;
          -  Current participation in an adherence intervention (unless proof in the&#xD;
             non-intervention arm)&#xD;
&#xD;
          -  plan to relocate out of Baltimore, Washington DC, or Philadelphia in next 18- months&#xD;
&#xD;
        Natal Female Inclusion Criteria:&#xD;
&#xD;
          -  Assigned female sex at birth&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  15-24 years old&#xD;
&#xD;
          -  Have friends who are gay or bisexual males or transgender females&#xD;
&#xD;
        Natal Female Exclusion Criteria:&#xD;
&#xD;
          -  Assigned male sex at birth&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Under age 15&#xD;
&#xD;
          -  Over age 24&#xD;
&#xD;
          -  No report of friends who are gay or bisexual males or transgender females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Celentano, ScD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renata Sanders, MD, ScM, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health and JHU School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Hailey-Fair, MPH, CPH</last_name>
    <phone>410-852-4070</phone>
    <email>khailey1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renata Sanders, MD, MPH, SCM</last_name>
    <phone>410-502-8166</phone>
    <email>rarring3@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Adolescent and Young Adult Health at Johns Hopkins Harriet Lane</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly I Hailey-Fair, MPH</last_name>
      <phone>410-852-4070</phone>
      <email>khailey1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renata Arrington-Sanders, MD, ScM, MPH</last_name>
      <phone>410-502-8166</phone>
      <email>rarring3@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Renata Arrington-Sanders, MD, ScM, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV young Black men who have sex with men substance use</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

